Scientists have developed a personalised platform tailored to patients' specific cancer mutations named TARDIS, which was able to accurately detect circulating tumour DNA (ctDNA) and signs of residual disease in 33 women with breast cancer.
Their...
More From BioPortfolio on "Personalised assay surpasses limits for detecting tumour DNA in breast cancer patients"